Instylla Announces the Appointment of Daniel Davis to Board of Directors
BEDFORD, Mass., – Apr 15, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolization, has announced the appointment of Daniel Davis to its Board of Directors. Mr. Davis is Chief Strategy Officer at Imperative Care, where he has led growth, development, and strategic initiatives for its stroke and vascular technologies. […]
Instylla Completes Submission of Premarket Approval Application for Embrace™ Hydrogel Embolic System
BEDFORD, Mass., – March 11, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the final module of its premarket approval application (PMA) for the Embrace™ Hydrogel Embolic System (HES).
Instylla Announces FDA Clearance of Tembo™ Embolic System
BEDFORD, Mass., – Jan 28, 2025 – Instylla, Inc., a privately held clinical-stage company developing solutions for peripheral vascular embolotherapy, has announced the FDA 510(k) clearance of the Tembo™ Embolic System. The Tembo Embolic System is a bioresorbable1 embolization agent comprised of irregularly shaped, dry gelatin particles of a size range from 85-255µm1…